The classification of central nervous system (CNS) tumors has evolved significantly with the integration of molecular markers, particularly through DNA methylation profiling.
We aimed to explore the disparity between epigenetic profiling, histomorphology, and CNS WHO grade by analyzing the therapeutic and survival duration of the patients.
